Insulin resistance (IR) is a crucial factor in metabolic disorders like non-alcoholic fatty liver disease (NAFLD) and polycystic ovary syndrome (PCOS), ...

Many of the talks led back to the mental health crisis, which has overtaken cancer and obesity to become the biggest global health concern. Industry leaders laid out their visions for alleviating the ...

AstraZeneca is the latest pharma company enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with ...

Discover how digital innovation in clinical trial technology—eClinical platforms, remote data capture, and decentralized ...

A team of researchers from Keio University School of Medicine, Kyoto Prefectural University of Medicine, and Teikyo ...

Scientists from the A*STAR Genome Institute of Singapore (A*STAR GIS) have developed a new artificial intelligence (AI)-based ...

AI guidance for clinicians aimed at reducing the spread of Clostridioides difficile—a bacteria that can be deadly for sick ...

The announcement builds on AZ's announcement earlier this year that it will invest $2.5 billion in an R&D facility in China, ...

AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

The technology’s potential to transform trials will need to be balanced with the challenge of instilling trust in participants.

Recent studies assessed artificial intelligence (AI) assistance tools in their ability to provide quality medical recommendations for patients.

Tempus will use its "Lens" data analytics platform to analyze and restructure genomic data from the the Abrams Research Center.